Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CHIEF EXECUTIVE OFFICER

COO GENERAL COUNSEL SECRETARY

CHIEF FINANCIAL OFFICER

CHIEF MEDICAL OFFICER

Chief Financial Officer

Chief Medical Officer

COO General Counsel Secretary

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-03	Premium	back to issuer	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2024-04-03	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-03	Premium	back to issuer	Premium	Premium	Premium	COO GENERAL COUNSEL SECRETARY
2024-04-03	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-03	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-03	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-03	Premium	back to issuer	Premium	Premium	Premium	-
2024-04-03	Premium	back to issuer	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	COO GENERAL COUNSEL SECRETARY
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2023-12-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-12-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2023-12-01	Premium	sold (taxes)	Premium	Premium	Premium	COO General Counsel Secretary
2023-09-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-09-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2023-09-01	Premium	sold (taxes)	Premium	Premium	Premium	COO General Counsel Secretary
2023-06-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2023-06-01	Premium	sold (taxes)	Premium	Premium	Premium	COO General Counsel Secretary
2023-06-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-05-08	Premium	bought	Premium	Premium	Premium	-
2023-05-08	Premium	bought	Premium	Premium	Premium	-
2023-05-05	Premium	bought	Premium	Premium	Premium	-
2023-05-05	Premium	bought	Premium	Premium	Premium	-
2023-05-04	Premium	bought	Premium	Premium	Premium	-

KNTE - Kinnate Biopharma Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for KNTE